Opportunity Information: Apply for RFA HG 21 026

The Non-Human Primate Developmental Genotype-Tissue Expression (NHP dGTEx) Project is a National Institutes of Health (NIH) funding opportunity (RFA HG 21 026) that supports the creation and operation of a centralized NHP dGTEx Research Center. The award mechanism is a U24 cooperative agreement, meaning the NIH will have substantial scientific and programmatic involvement in the project rather than operating strictly as a hands-off funder. The activity focus sits in the health and genomics space (CFDA 93.172), and the announcement specifies "Clinical Trials Not Allowed," so the work is intended to be resource-building, genomics, and comparative biology rather than interventional human or animal clinical trials.

The core purpose of the center is to build a high-value community resource that maps how gene expression changes across tissues and developmental time in non-human primates, and then relates those patterns to what is known in humans. The opportunity lays out four major functions. First, the center is expected to create a well-curated tissue resource spanning multiple reference tissues collected across developmental stages in non-human primates. This implies a structured, systematic approach to sample collection and annotation so that the resulting specimens are broadly useful as reference material for the research community. Second, the center will generate molecular data from those tissues, specifically transcriptome sequencing and other genomic analyses, and it is expected to cover both bulk tissue measurements and single-cell populations. In practice, that points toward a combination of approaches such as bulk RNA sequencing for overall tissue-level expression patterns and single-cell or single-nucleus methods to resolve cell-type-specific expression programs, plus complementary genomics assays as appropriate.

Third, beyond generating specimens and raw data, the center must perform analyses that characterize gene expression patterns in non-human primates and explicitly compare them to human gene expression patterns. This comparative component is central: the project is meant to illuminate where developmental gene regulation is conserved between NHPs and humans, where it diverges, and how those similarities and differences vary across tissues and developmental windows. This kind of cross-species expression atlas can be used to improve translational interpretation of NHP studies, refine model selection for human biology questions, and provide context for human genomic findings by anchoring them to closely related primate developmental biology.

Fourth, the center is responsible for making both the tissue samples and the resulting data available and usable to the wider scientific community. "Usable" is doing a lot of work here: it suggests expectations around data quality, standardized metadata, clear documentation, and practical access mechanisms so external researchers can find, request, and analyze the materials without needing insider knowledge. For a project like this, usability typically depends on consistent sample processing, rigorous quality control, harmonized ontologies for tissues and developmental stages, and release practices that support downstream computation and integration with existing human resources such as GTEx-style datasets.

Eligibility is broad and includes many common NIH-eligible organization types: state, county, and local governments; special districts; independent school districts; public and private institutions of higher education; federally recognized tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status; for-profit organizations (other than small businesses) and small businesses; and other eligible entities. The announcement also explicitly calls out additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions. At the same time, it draws a clear boundary around foreign involvement: non-domestic (non-U.S.) entities and non-domestic components of U.S. organizations are not eligible to apply. However, foreign components (as defined by the NIH Grants Policy Statement) are allowed, which typically means a U.S.-based applicant can include certain scientifically justified activities performed outside the U.S. under NIH rules, even though a foreign institution cannot serve as the applicant organization.

The opportunity was created on 2021-06-03 with an original application closing date of 2021-08-02. The source excerpt does not provide an award ceiling or the expected number of awards, so those details would need to be confirmed in the full funding announcement text or NIH documentation. Overall, the grant is designed to stand up a coordinated, NIH-partnered center that produces a developmental, multi-tissue NHP gene expression and genomics resource, analyzes it in direct comparison to human expression patterns, and distributes both biospecimens and high-quality datasets in a way that accelerates broader research use.

  • The National Institutes of Health in the health sector is offering a public funding opportunity titled "Non-Human Primate Developmental Genotype-Tissue Expression (NHP dGTEx) Project (U24 Clinical Trials Not Allowed)" and is now available to receive applicants.
  • Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.172.
  • This funding opportunity was created on 2021-06-03.
  • Applicants must submit their applications by 2021-08-02. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
  • Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
Apply for RFA HG 21 026

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:

FAQs: Non-Human Primate Developmental Genotype-Tissue Expression (NHP dGTEx) Project (RFA HG 21 026)

What is the NHP dGTEx Project funding opportunity?

The Non-Human Primate Developmental Genotype-Tissue Expression (NHP dGTEx) Project is a National Institutes of Health (NIH) funding opportunity (RFA HG 21 026) to create and operate a centralized NHP dGTEx Research Center.

What is being funded under this opportunity?

This opportunity supports a single, centralized research center that builds a community resource mapping gene expression across tissues and developmental time in non-human primates (NHPs) and comparing those patterns to humans, while also making tissues and data broadly available to the research community.

What award mechanism is used for this grant?

The award mechanism is a U24 cooperative agreement.

What does it mean that this is a U24 cooperative agreement?

A U24 cooperative agreement indicates NIH will have substantial scientific and programmatic involvement in the project. In other words, NIH is expected to be an active partner in the effort rather than acting strictly as a hands-off funder.

What is the general scientific area or focus of this program?

The activity focus is in health and genomics, associated with CFDA 93.172. The work emphasizes resource-building, genomics, and comparative biology.

Are clinical trials allowed?

No. The announcement specifies "Clinical Trials Not Allowed."

If clinical trials are not allowed, what kind of work is expected instead?

The described work centers on building reference tissue resources, generating genomic and transcriptomic datasets (including single-cell and bulk approaches), performing comparative analyses between NHP and human gene expression, and distributing tissues and data to the broader community.

What are the main expected functions of the NHP dGTEx Research Center?

The opportunity describes four major functions: (1) creating a curated tissue resource across multiple reference tissues and developmental stages in NHPs; (2) generating molecular data including transcriptome sequencing and other genomic analyses, covering both bulk tissues and single-cell populations; (3) analyzing NHP gene expression patterns and comparing them to human gene expression patterns; and (4) making tissues and data available and usable to the wider scientific community.

What does "create a well-curated tissue resource" imply?

It implies a structured, systematic approach to tissue collection and annotation across developmental stages and multiple reference tissues, so specimens can serve as broadly useful reference material for the research community.

What types of molecular data are expected to be generated?

The center is expected to generate transcriptome sequencing data and other genomic analyses from the collected tissues. The scope explicitly includes both bulk tissue measurements and single-cell populations.

Does the opportunity require single-cell data, bulk data, or both?

Both. The announcement indicates an expectation to cover bulk tissue measurements and single-cell populations.

Is comparative analysis with humans a required component?

Yes. A central requirement is to characterize gene expression patterns in NHPs and explicitly compare them to human gene expression patterns.

What is the purpose of comparing NHP and human gene expression patterns?

The comparative component is intended to identify what aspects of developmental gene regulation are conserved or divergent between NHPs and humans across tissues and developmental windows, improving translational interpretation and providing context for human genomic findings.

What does it mean that the center must make tissues and data "available and usable"?

It means the center is expected not only to generate samples and datasets, but also to distribute them in a way that external researchers can realistically find, request, and analyze them. The description points to expectations around data quality, standardized metadata, clear documentation, and practical access mechanisms.

Who is eligible to apply?

Eligibility is broad and includes state, county, and local governments; special districts; independent school districts; public and private institutions of higher education; federally recognized tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status; for-profit organizations (other than small businesses) and small businesses; and other eligible entities.

Are minority-serving institutions and community-based organizations eligible?

Yes. The announcement explicitly calls out Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving Institutions, HBCUs, TCCUs, faith-based or community-based organizations, regional organizations, and U.S. territories or possessions as eligible applicant types (among others).

Can a non-U.S. (foreign) organization apply as the applicant?

No. Non-domestic (non-U.S.) entities are not eligible to apply as the applicant organization.

Are non-domestic components of U.S. organizations eligible to apply?

No. Non-domestic components of U.S. organizations are not eligible to apply.

Are foreign components allowed at all under this opportunity?

Yes. While foreign organizations cannot be the applicant, foreign components (as defined by the NIH Grants Policy Statement) are allowed. This generally means a U.S.-based applicant may include certain scientifically justified activities performed outside the U.S. under NIH rules.

What is the opportunity number or identifier?

The NIH funding opportunity is identified as RFA HG 21 026.

When was this opportunity created and what was the application closing date?

The opportunity was created on 2021-06-03, and the original application closing date was 2021-08-02.

How many awards will be made and what is the award ceiling?

The provided information does not state an award ceiling or the expected number of awards. Those details would need to be confirmed in the full funding announcement text or related NIH documentation.

What is the intended end product or outcome of the funded center?

The intended outcome is a coordinated, NIH-partnered center that produces a developmental, multi-tissue NHP gene expression and genomics resource, performs direct comparisons to human expression patterns, and distributes both biospecimens and high-quality datasets to accelerate broader research use.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Health

Next opportunity: Klamath River Coho Restoration Grant Program (Program) Administration

Previous opportunity: Children, Youth and Families At-Risk Sustainable Community Projects

Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for RFA HG 21 026

 

Applicants also applied for:

Applicants who have applied for this opportunity (RFA HG 21 026) also looked into and applied for these:

Funding Opportunity
NIH Directors Transformative Research Awards (R01 Clinical Trial Optional) Apply for RFA RM 21 017

Funding Number: RFA RM 21 017
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent
Shared Personal Protective Equipment (PPE) Resources (S10 Clinical Trial Not Allowed) Apply for PAR 21 257

Funding Number: PAR 21 257
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent
Integration, Dissemination, and Evaluation (BRIDGE) Center for the NIH Bridge to Artificial Intelligence (Bridge2AI) Program (U54 Clinical Trial Not Allowed) Apply for RFA RM 21 023

Funding Number: RFA RM 21 023
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent
Large Research Projects for Prevention of Healthcare-Associated Infections (R01) Apply for PA 21 265

Funding Number: PA 21 265
Agency: Agency for Health Care Research and Quality
Category: Health
Funding Amount: $500,000
High Resolution Mapping of Biomolecules in Brain Cells in Aging and Alzheimers Disease (R01 Clinical Trial Not Allowed) Apply for RFA AG 22 019

Funding Number: RFA AG 22 019
Agency: National Institutes of Health
Category: Health
Funding Amount: $500,000
Promoting Bunyavirales Basic Science Research (R01 Clinical Trial Not Allowed) Apply for RFA AI 21 046

Funding Number: RFA AI 21 046
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent
NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurial Small Business Transition Award (R41/R42 Clinical Trial Optional) Apply for RFA AG 22 014

Funding Number: RFA AG 22 014
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent
NIA Research and Entrepreneurial Development Immersion (REDI): Mentored Entrepreneurial Career Development Award (K01 Clinical Trial Not Allowed) Apply for RFA AG 22 004

Funding Number: RFA AG 22 004
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent
NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurial Small Business Transition Award (R43/R44 Clinical Trial Optional) Apply for RFA AG 22 007

Funding Number: RFA AG 22 007
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent
NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurship Enhancement Award (R25 Clinical Trial Not Allowed) Apply for RFA AG 22 003

Funding Number: RFA AG 22 003
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent
Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required) Apply for PAR 21 240

Funding Number: PAR 21 240
Agency: National Institutes of Health
Category: Health
Funding Amount: $225,000
Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative UG3/UH3 Clinical Trial Required) Apply for PAR 21 243

Funding Number: PAR 21 243
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent
Data Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative U24 Clinical Trial Required) Apply for PAR 21 242

Funding Number: PAR 21 242
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent
NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required) Apply for PAR 21 241

Funding Number: PAR 21 241
Agency: National Institutes of Health
Category: Health
Funding Amount: $350,000
Role of Adaptive Immunity in Etiology of Alzheimers Disease and Alzheimers Disease-Related Dementias (R01 Clinical Trial Optional) Apply for RFA AG 22 017

Funding Number: RFA AG 22 017
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent
Leveraging Existing Large Databases and Cohorts to Better Understand the Risks and Benefits of Long-Term Osteoporosis Therapy and Drug Holiday (R01 Clinical Trial Not Allowed) Apply for RFA AG 22 018

Funding Number: RFA AG 22 018
Agency: National Institutes of Health
Category: Health
Funding Amount: $750,000
Disaster Risk Management Apply for 720 663 21 RFI 00007

Funding Number: 720 663 21 RFI 00007
Agency: Ethiopia USAID-Addis Ababa
Category: Health
Funding Amount: $8,000,000
Mechanisms of Alcohol Tolerance (R21/R33 Clinical Trial Optional) Apply for PAR 21 250

Funding Number: PAR 21 250
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent
India Collaborative Vision Research Program (R01 Clinical Trial Not Allowed) Apply for PAR 21 249

Funding Number: PAR 21 249
Agency: National Institutes of Health
Category: Health
Funding Amount: $250,000
Prevention of Perinatal Depression: Improving Intervention Delivery for At-Risk Individuals (R34 Clinical Trial Required) Apply for RFA MH 21 241

Funding Number: RFA MH 21 241
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

Inside Our Applicants Portal

  • Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
  • Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
  • Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Access Applicants Portal

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Learn More

 

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "RFA HG 21 026", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.

 

Ask a Question: